The Next Chapter in Diabetes Management is Here

Discover Sequel, making the next chapter the best chapter

As a driven team of innovators and problem solvers focused on improving the health and lives of people with diabetes, we’re redefining what diabetes care looks like.

Sequel is Changing the Future of Diabetes Management

Around 63%¹ of people with diabetes requiring insulin therapy are currently not using AID systems, a result of challenges that still exist in delivering optimal diabetes care.

Sequel removes the barriers for accessible revolutionary insulin therapy, so more people with diabetes can improve their health and wellbeing.

Simplified Access

Delivering the most affordable AID system through pharmacy channels*.

*Pharmacy availability coming soon

Advanced Technology

Created for everyday wear with precise measurement technology to help ensure accurate insulin delivery.²

Personalized Control

Automatically adjusts insulin delivery and powered by the Tidepool algorithm demonstrating real-world evidence of clinically meaningful benefits.

1 March 2024, Seagrove Partners GlobeVIEW Forecast Model.
2 twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide, Sequel Med Tech: DKPI-09233-001 1.3 2024-02-23.

Introducing the twiist™ Automated Insulin Delivery (AID) System Powered by Tidepool

The twiist AID system is the first drug delivery system that directly measures the volume of insulin delivered with every microdose. The system offers the flexibility to address individual dosing needs, while providing accurate insulin delivery to help achieve tighter glucose control.

The twiist system is FDA-cleared for people ages 6 and up with type 1 diabetes. The twiist AID system is intended for single-patient use and requires a prescription.

A Company with a Rich History in Diabetes Innovation

Sequel was co-founded by legendary inventor Dean Kamen, who invented the first wearable insulin pump known as the ‘blue brick’ (AutoSyringe) in the 1970s.

Over 40 years later, DEKA Research & Development Corp. have partnered with Sequel to rewrite the next chapter on AID technology for people with diabetes by leveraging the advancement in continuous glucose monitoring and intuitive algorithms.

We're Not Stopping at Revolutionary Type One Diabetes Technology

Sequel continues to provide extraordinary support in advancing the care of people with diabetes. And that’s just the beginning in advancements developed by Sequel.